Three major drug middlemen needlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...